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Poster Session II 115(n 5 10), NHL (n 5 7), Hodgkin’s lymphoma (n 5 6), advanced
CML (n5 4), and advanced CLL (n5 4). 9 pts had previously un-
dergone autografting. 80% received HLA-identical grafts. All pts
were conditioned with fludarabine (30 mg/m2/day, days -7 to -3),
busulfan (0.8 mg/kg/dose IV  8 doses) and rabbit ATG (2.5 mg/
kg/day, days -4 to -2) followed by micro-dose methotrexate and ta-
crolimus. Stem cell source included peripheral blood (n 5 26) or
bone marrow (n 5 4). All pts engrafted neutrophils and platelets
promptly (median 15 and 16 days, respectively). There were no pri-
mary graft failures. Rates of grade II-IV and III-IV aGVHD were
43% (n5 13) and 23% (n5 7) respectively. 9 pts (30%) developed
cGVHD but extensive cGVHD was seen in only 10% (n5 3). Day
100 TRM was 10% (n5 3). CMV and EBV reactivation occurred in
30% (n 5 9) and 20% (n 5 6) respectively. 2 pts developed PTLD
requiring rituximab. 3 pts had BK-virus associated hemorrhagic
cystitis. Chimerism analysis showed 100% donor CD331 at all
time points (days 30, 60, 100) and median donor CD31 chimerism
of 94% at day 130 and 100% at day 1100. One pt had secondary
graft failure. 23 pts (76%) were in CR after SCT. Kaplan-Meier es-
timates of overall survival (OS) and progression free survival (PFS)
at 1 year are 62% and 43% respectively. OS (P 5 0.95) and PFS (P
5 0.65) was not statistically significant between recipients of
matched and mismatched grafts. In conclusion, FBA and tacrolimus
based GVHD prophylaxis achieved rapid donor chimerism and a fa-
vorably low incidence of TRM and cGVHD despite being tested in
poor risk pts. However the rates of EBV reactivation and disease re-
lapse warrant further exploration of this approach using lower doses
of ATG (e.g. 5–6 mg/kg total dose).311
ALLOGENIC STEM CELL TRANSPLANTATION IN PATIENTS WITH AC-
QUIRED APLASTIC ANEMIA AND FANCONNI ANEMIA: A SINGLE CENTER
EXPERIENCE OVER 11 YEARS
Rosales, C., Abello, V., Esguerra, H.J., Pedraza, E., Linares, A.,
Rosales, M.L. Clınica de Marly, Bogota, Colombia.
We performed a retrospective analysis, of allogenic stem cell
transplantation (allo-SCT) results, in 40 patients with diagnosis of
acquired aplastic anemia or Fanconni Anemia, in a transplant center
in Bogota, Colombia, between 1996 and 2007.
During that period, 42 transplants were performed in 40 patients.
28 (70%) acquired aplastic anemia and 12 (30%) Fanconni’s Ane-
mia. 17 (42.5%) female/25 (62.5%) male. Mean age was 22 years
(4–57).
Stem cells were obtained from peripheral blood in 36 (90%) and
from bone marrow in 6 (15%). The majority of patients were of
high risk; the mean time from diagnosis to transplant was 27.8 months
(2–141) and 57.5% of them had received more than 20 transfusions
before transplantation. Patients were conditioned with Cy-ATG in
24 (57.1%), high dose Cyclophosphamide (Cy) in 11 (26.2%), fludar-
abine-Cy-ATG in 3 (7.14%) and Alemtuzumab-Cy in 4 (9.52%).
Mean CD341 cell dose was 3.3 (1.08–6.66), TNC: 9.7 (1.2–
59.2).
Neutrophil engraftment was achieved at day 116 (3–54) post-
transplantation.
At a mean follow up of 19.5 months (7–128), overall survival is
65%.
Comparison of results of different conditioning regimens shows
that overall survival for patients conditioned with Cy alone is disap-
pointing, 8/11 patients died, 6 due to GVHD and 2 due to infection.
After adding ATG to Cy, mortality due to GVHD was significantly
reduced. Only 7/24 patients died, GVHD was the cause of death
only in 2. Infection was the cause of death in other 4. 2 patients
had secondary graft failure, one died. The other received a second
transplant and is alive with mixed chimerism, but free of transfusion
support.
Of 4 patients treated with alemtuzumab containing regimens, 3
had secondary graft failure, 2 died, and one received a second trans-
plant successfully.
On this group of patients Cy-ATG was the best conditioning reg-
imen in terms of overall survival and GVHD incidence. The major-
ity of patients in this cohort were remitted to transplant late in their
disease, early treatment will probably improve the outcomes, as it
has been confirmed in other papers.312
DOG LEUKOCYTE ANTIGEN (DLA)-IDENTICAL SIBLING CORD BLOOD
TRANSPLANTATION (CBT) FOLLOWING MYELOABLATIVE TOTAL
BODY IRRADIATION (TBI)
Lesnikov, V.1, Baran, S.1, Abrams, K.1, Zellmer, S.1, Yang, Y.-J.1,
Heimfeld, S.1, Lesnikova, M.1, Nash, R.A.1,2, Georges, G.E.1,2. 1Fred
Hutchinson Cancer Research Center, Seattle, WA; 2University of
Washington, Seattle, WA.
Cord blood (CB) is increasingly used for hematopoietic cell
transplantation due to its rapid availability and less stringent HLA
matching requirements. However, low cell dose of CB units and de-
layed engraftment remain significant obstacles for increased use of
CBT in adults. We aim to develop a large animal model of CBT
by using outbred dogs to improve the understanding of engraftment
across histocompatibility barriers and cell dose limitations of CBT.
We harvested and cryopreserved individual units of canine CB ob-
tained from litters following Caesarian section at day 54 to 60 of
gestation. We asked if single or multiple units of DLA-identical sib-
ling CB could engraft in DLA-identical recipient dogs. Eight adult
dogs received 920 cGy TBI followed by intravenous infusion of
thawed CB, either a single CB unit (n 5 3) or multiple [2 to 4]
CB units (n 5 5) with a combined total nucleated cell (TNC)
dose range 0.3–2.6  107/kg. Transplanted total CD341 cell dose
was 0.2–2.5  105/kg. Postgrafting immunosuppression was cyclo-
sporine 1 mycophenolate mofetil for 35 and 28 days, respectively.
G-CSF was given until recovery of neutrophil counts. Three dogs
died on days 13–17 due to neutropenic sepsis. Five dogs engrafted
and survived; and are currently 265–621 days after CBT. Sustained
neutrophil recovery.1000/mL occurred 29–35 days after CBT, and
platelet recovery .20,000/mL was 38–84 days after CBT. Monthly
chimerism analysis was assessed by PCR using informative microsa-
tellite markers. Among each of the 4 surviving recipients of multiple
unit CBT, all transplanted donor CB units contributed to hemato-
poiesis with sustained multi-donor chimerism. However, in all 4
dogs, 1 of the CB units eventually dominated hematopoiesis with
sustained 75–95% donor chimerism. In all cases the dominant CB
unit had the highest TNC dose. There was no acute or chronic
GVHD. From 3–8 months after CBT, immune reconstitution stud-
ies normalized including T cell proliferation allo-stimulation index,
1o and 2o immune response to sheep red blood cells and recovery of
the absolute number of CD4 and CD8 T-cell subsets. In summary,
cryopreserved DLA-identical CB successfully engrafted and pro-
vided durable hematopoietic recovery. There was stable multi-do-
nor chimerism and the CB unit with the greatest TNC dose
predicted the dominant donor graft. The approximate minimum
cell dose threshold for successful engraftment of a single CB unit
with this conditioning regimen model was 0.8  107 TNC/kg.313
TACROLIMUS DOSING IN ALLOGENEIC HEMATOPOIETIC STEM-CELL
TRANSPLANTATION RECIPIENTS RECEIVING VORICONAZOLE
Trifilio, S.M., Pi, J., Singhal, S., Frankfurt, O., Evens, A., Gordon, L.,
Tallman,M.,Winter, J., Williams, S., Mehta, J. Northwestern Univer-
sity, Chicago.
Tacrolimus (TAC) is primarily metabolized by the CYP450 3A4
isoenzyme. Voriconazole, often used to prevent fungal infections af-
ter allogeneic HSCT, is metabolized by the CYP450 3A4, 2C9 and
2C19 isosenzymes. Clinical trials in healthy volunteers have shown
significant drug interactions between the two requiring TAC dose
reduction. Ordinarily, TAC is started at the dose of 0.03 mg/kg
IV daily on day -1. After starting it at this dose and having to reduce
the dose substantially within 2–3 days in all patients receiving con-
comitant voriconazole 200 mg twice daily orally from day 0, we im-
plemented a simple, preemptive TAC dose reduction strategy to
maintain steady-state levels between 5 and 15 ng/mL. As a first
step, IV TAC was initiated at the reduced dose of 0.022 mg/kg/
day. As a second step, dose was reduced by 30–40% if the steady-
state level 48 h after initiation of TAC (day 11) was between 7
and 10 ng/mL, and by 40–50% if the level was between 10 and 15
ng/mL. No change was made if the level was\7 ng/mL. Subse-
quently, levels were monitored 2–3 times a week and the dose
116 Poster Session IIadjusted as needed. Here, we evaluate the pharmacokinetic effects of
concomitant voriconazole administration on blood TAC levels in
27 consecutive allogeneic HSCT recipients (28–64 y; median 55)
in whom pre-emptive dose-modification was used during the first
2 weeks. A total of 170 levels (3–12 per patient; median 5) were
checked between day11 and day116. None of the levels was sub-
therapeutic (\5 ng/mL), and 34 (20%) were .15 ng/mL. 24 of 27
patients required dose-reduction from day 0 to day 11 based on
levels. Each patient required dose-reduction at least twice. An
increase in the dose was needed in only 2 patients after initial
dose-reduction. TAC doses (median, range) on days 0, 7 and 14
were 1.6 (1–2), 0.6 (0.13–1.4), and 0.4 (0.13–1.1) respectively indi-
cating that the median absolute TAC dose, the median TAC mg/
kg dose, and the median per cent TAC dose (100% being the base-
line) declined substantially. However, the median TAC level over
the first 2 weeks remained between 10 and 14.5. It is clear that
lack of pre-emptive dose-reduction would have resulted in TAC
levels climbing steadily. Based on this, we recommend starting
TAC at 0.02–0.022 mg/kg rather than at 0.03 mg/kg if patients
are on concomitant voriconazole, checking levels regularly, and re-
ducing the dose by 30–40% if the 48-h level is 7–10 and by 40–50%
if it is 10–15.314
LOW RELAPSE RATE AFTER ALLOGENEIC-SCT FOLLOWING A MYELOA-
BLATIVE PREPARATIVE REGIMEN WITH FLAMSA CHEMOTHERAPY AND
TOXICITY-REDUCED CONDITIONING IN PATIENTS WITH HIGH RISK
MYELOID MALIGNANCIES AGED 60 YEARS OR OLDER
Schleuning, M.1, Judith, D.1, Heshmat, M.1, Burlakova, I.1, Taube, R.1,
Jedlickova, Z.1, Baurmann, H.1, Kolb, H.-J.2, Schwerdtfeger, R.1. 1Ger-
man Diagnostic Clinic Foundation, Wiesbaden, Germany; 2University of
Munich and GSF Research Center for Environment and Health,Munich,
Germany.
With the introduction of toxicity-reduced conditioning (TRC)
allogeneic stem cell transplantation (allo-SCT) may be considered
also for elderly patients (pts). However, non-myeloablative regi-
mens are associated with a high relapse risk. Our strategy combined
intensive chemotherapy to induce a status of minimal residual dis-
ease, TRC, GVHD prophylaxis with in vivo T-cell depletion and
adjuvant donor lymphocyte transfusions (aDLT). This report sum-
marizes our cumulative experience in a cohort of 45 consecutive el-
derly pts (60–70 y, median 63 y) with myeloid malignancies (18 with
high risk cytogenetics) treated with the FLAMSA-RIC protocol,
consisting of a 4-day course of chemotherapy (AraC 2 g/m2, Fludar-
abine 30 mg/m2 and Amsacrine 100 mg/2) followed by 3 days rest
and TRC with 4Gy TBI, cyclophosphamide and antithymocyte
globuline prior to allo-SCT. The underlying diseases were AML
(de novo n 5 20; sAML n 5 16) or progressive MDS (n 5 8) with
only 5 pts being in CR at the time of transplant. One pt suffered
from CML in refractory myeloid blast crisis. To further reduce tox-
icity TBI was replaced by intravenous Busulfan (8  3.2 mg/kg) in
the last 16 pts. All but one pt received mobilized peripheral blood
stem cells as graft and 9 pts had a sibling and 36 an unrelated donor.
GVHD prophylaxis consisted of Cyclosporine A and MMF. The
procedure as a whole was clearly myeloablative as evidenced by
full donor chimerism at d1 30 in all pts. Engraftment occurred af-
ter 10–48 d (median 18 d). Of 25 eligible pts (being alive and free of
leukaemia at d 1 120) 8 pts actually received aDLT and none of
these relapsed. Despite the high relapse risk we observed only 6
deaths because of recurrent leukaemia. Severe acute GVHD oc-
curred in 20% and the non relapse mortality was 31% with 3 pts dy-
ing from GVHD, 10 from infection and one from cardiac failure.
With a median follow-up of 10 months for surviving pts the Ka-
plan-Meyer procedure estimates a 43% probability of survival at 2
y after transplantation. Although, the follow-up of pts having re-
ceived i.v. Busulfan is rather short there seems to be a strong ten-
dency of further reduced toxicity without increased relapse
incidence in this cohort. Our data support the notion that toxic-
ity-reduced but still myeloablative conditioning followed by allo-
SCT from related or unrelated donors can safely be applied in el-
derly pts with high risk myeloid malignancies and provides an excel-
lent platform for adoptive immunotherapy after induction of
tolerance.315
SIMILAR SURVIVAL AFTER SIBLING VS UNRELATED DONOR ALLOGE-
NEIC STEM CELL TRANSPLANTATION WITH REDUCED INTENSITY CON-
DITIONING
Stein, S., Goldstein, S.C., Smith, J., Luger, S., Loren, A.,
Stadtmauer, E., Schuster, S., Nasta, S., Tsai, D., Perl, A.,
Andreadis, B., Frey, N., Kasner, M., Cole, S., Hinkle, J., Porter, D.L.
Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
Although recent studies have shown comparable survival out-
comes between unrelated donor (URD) and sibling donor stem
cell transplantation in the myeloablative transplant setting, little
comparative data based on donor source is available in the setting
of non-myeloablative/reduced intensity conditioning (RIC), where
it is presumed that GvL effects must play a key role in long term sur-
vival. In this retrospective analysis, we compare the outcome of 111
patients receiving RIC followed by either matched sibling (n 5 65)
or unrelated donor (n 5 46) peripheral blood stem cell (PBSC)
transplantation for hematologic malignancies. All patients were
deemed ineligible for myeloablative conditioning based on institu-
tional standards for age, comorbid disease, and/or prior therapy. All
sibling and 38 of 46 unrelated recipients received A, B, DR matched
grafts. The median recipient age in both cohorts was identical; sib-
ling 52 y (range 12–75 y) and unrelated 52 y (range 29–69 y). Con-
ditioning regimens were primarily fludarabine/cytoxan-based in
both cohorts, with URD recipients skewed toward the addition of
Alemtuzumab pre-transplant (69% URD vs 25% sib), and the use
of TBI 200 for 21/23 myeloma pts. The distribution of diagnoses
was similar between both cohorts in patients with lymphoid malig-
nancies (NHL, HD, CLL n5 66) 34 sib vs 32 URD, and leukemia/
MDS (n5 22), 10 sib vs 12 URD; the diagnosis of myeloma (n5 23)
was skewed toward sibling donors (21 vs 2 URD). Kaplan-Meier es-
timate of overall survival (OS) for all patients at 2 years was 31%. At
a median f/u of 43 weeks in both cohorts, overall survival was nearly
identical (57% sibs; 55% URD). Of note, there was no statistically
significant difference in 2 year OS between sibling and URD recip-
ients (p5 0.25), nor was there a difference in K-M estimates of OS
between sibling and URD recipients when patients with lymphoid
and myeloid disease were analyzed separately. Among expired pa-
tients, there was no difference in the incidence of disease-related
(26/42 sibs vs 18/32 URD) or treatment-related [organ failure,
infection and GvHD] (16/42 sibs vs 14/32 URD) causes of death.
Furthermore, a statistically significant higher proportion of
GvHD-related death among URD patients was not seen. These
data support the pursuit of unrelated donors for RIC transplanta-
tion as an alternative to sibling donors without compromising over-
all survival.316
DEVELOPMENT AND ANTI-BALB.B REACTIVITY OF T CELLS EMERGING
FROM BONE MARROW CELLS TRANSDUCEDWITH A CLONAL TCRVb14-
Jb2.4 SEQUENCE
Appel, M.Y.1, Friedman, T.M.2, Korngold, R.2. 1Thomas Jefferson Uni-
versity, Philadelphia, PA; 2Hackensack University Medical Center,
Hackensack, NJ.
In previous experiments utilizing spectratype-sequencing, we re-
ported a dominant T cell receptor (TCR) Vb14-Jb2.4 sequence
prevalent in the thoracic duct lymphocyte (TDL) population of ir-
radiated BALB. B mice transplanted with C57BL/6 (B6) mouse
bone marrow and CD81 T cells. CD4-dependent CD81 Vb141
T cells mediate lethal graft versus host disease (GVHD) in
a B6/BALB. B transplantation model. Therefore, we wanted to
investigate the alloreactive potential of T cells expressing the partic-
ular isolated TCRb sequence. We harvested bone marrow from 5-
fluorouracil (5-FU) treated TCRb-/- mice. The bone marrow cells
were retrovirally transduced with a construct containing the cDNAs
for Green Fluorescent Protein (GFP) and the specific Vb14-Jb2.4
TCR sequence. The marrow was then used to reconstitute irradi-
ated B6 mice. 20–40% of the peripheral blood mononuclear cells
(PBMC) in these mice were GFP1Vb141, of which greater than
95% were CD41 and 1–4% were CD81. When the marrow was
used to reconstitute MHC II-/- mice, bred to a B6 background,
